Meta-Analysis Study Yields Significant Results For EcoNugenics®’ PADMA Formula
SANTA ROSA, Calif., September 23, 2004 - Tibetan herbal formula PADMA, exclusively distributed in the United States by EcoNugenics, Inc.®, has been proven to be effective in promoting circulation and aiding in treatment of peripheral arterial occlusive diseases (PAOD). Dr. Jörg Melzer from the University of Zurich, Department of Natural Medicine in Zurich, Switzerland has announced the promising results of his systematic review and meta-analysis on clinical data of PADMA.
“The new data shows PADMA as an effective means of promoting circulation and increasing physical activity levels in PAOD patients,” states Isaac Eliaz, M.D., L.Ac., chairman of EcoNugenics and medical director of Amitabha Medical Clinic and Healing Center. “The advantages of using a multi-compound formula such as PADMA, rather than a single compound, are evident in its 30 years of continued usage in Switzerland.”
The six, double-blind, placebo-controlled studies consisted of the data of 444 patients (average age of 63; 64 percent males) diagnosed with stable PAOD Fontaine stage IIb. After four months patients treated with PADMA showed a marked increase in treadmill walking distance.
PADMA is a multi-compound Tibetan herbal formula that consists of 22 compounds: 20 herbal ingredients, camphor and calcium sulphate. Additional studies have suggested that the PADMA formula may be effective in supporting the immune system, promoting healthy circulation and supporting antioxidant activity. PADMA is sold as a drug and as a nutritional supplement in Europe. The same PADMA is sold in North America, distributed by EcoNugenics, as PADMA BASIC®.
EcoNugenics was founded in 1995 with a commitment to offering premium dietary supplements and nutraceuticals based on the best of modern science integrated with the ancient wisdom of traditional and complementary therapies. They are committed to five basic principles, which include innovation in product formulation, thorough scientific research, ongoing clinical validation, customer education and empowerment and superior quality control. For more information on the PADMA product line contact EcoNugenics at 800.308.5518 or www.econugenics.com. For additional inquiries or to request a copy of the study contact Amanda Holty at [email protected] or 801.538.0777 ext. 106.
# # #
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
 Melzer J, Brignoli R, Diehm C, Reichling J, Do Dai-Do, Saller R, A systematic review and meta-analysis on clinical data of, PADMA, a Tibetan herbal multi-compound formula, in the treatment of peripheral arterial occlusive disease (PAOD)
Email Address: [email protected]
Telephone: (801) 538-0777, ext. 106